Current and emerging options for the drug treatment of narcolepsy

Drugs

Volumn 73, Issue 16, 2013, Pages 1771-1781

  De La Herrán Arita, Alberto K ^a   García García, Fabio ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSIDAD VERACRUZANA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYRIC ACID; 6 (3 CYCLOBUTYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 YLOXY) N METHYLNICOTINAMIDE; ADRAFINIL; AMPHETAMINE; ANTIHISTAMINIC AGENT; ARMODAFINIL; ATOMOXETINE; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; HISTAMINE; HISTAMINE H3 RECEPTOR ANTAGONIST; IMIPRAMINE; JNJ 17216498; JNJ 28583867; METHYLPHENIDATE; MILNACIPRAN; MODAFINIL; NISOXETINE; NORTRIPTYLINE; OREXIN A; OREXIN B; OROTIRELIN; OXYBATE SODIUM; PITOLISANT; PROTRIPTYLINE; TALTIRELIN; UNCLASSIFIED DRUG; VENLAFAXINE; VILOXAZINE;

ANHEDONIA; ANOREXIA; ANTIDEPRESSANT ACTIVITY; ATTENTION DEFICIT DISORDER; BEDTIME DOSAGE; BEHAVIOR MODIFICATION; BLOOD BRAIN BARRIER; CATAPLEXY; COCAINE DEPENDENCE; CONSTIPATION; DAYTIME SOMNOLENCE; DEPRESSION; DIET RESTRICTION; DROWSINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENANTIOMER; EPWORTH SLEEPINESS SCALE; ERYTHEMA MULTIFORME; FOREBRAIN; GASTROINTESTINAL SYMPTOM; HISTAMINE BLOOD LEVEL; HUMAN; HYPNAGOGIC HALLUCINATION; LIFESTYLE MODIFICATION; LOCUS CERULEUS; MORBIDITY; MULTIPLE SCLEROSIS; MUSCLE TONE; NARCOLEPSY; NAUSEA; NIGHT SLEEP; NONHUMAN; NUCLEUS ACCUMBENS; PARASOMNIA; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHOTOSTIMULATION; PHYLOGENY; PREFRONTAL CORTEX; QUALITY OF LIFE; RECEPTOR BINDING; REM SLEEP; REVIEW; SCHIZOPHRENIA; SHIFT WORKER; SIDE EFFECT; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SLEEP WAKING CYCLE; SLOW WAVE SLEEP; SWEATING; WAKEFULNESS; XEROSTOMIA;

ANIMALS; HUMANS; NARCOLEPSY; SLEEP; SLEEP DISORDERS;

EID: 84889029747     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0127-y     Document Type: Review

References (73)

1. Longstreth WT Jr, Koepsell TD, Ton TG, Hendrickson AF, van Belle G. The epidemiology of narcolepsy. Sleep. 2007;30:13-26.
2. Broughton R, Dunham W, Newman J, Lutley K, Duschesne P, Rivers M. Ambulatory 24 hour sleep-wake monitoring in narcolepsy-cataplexy compared to matched controls. Electroencephalogr Clin Neurophysiol. 1988;70:473-81.
3. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355:39-40.
4. De la Herrán-Arita AK, Guerra-Crespo M, Drucker-Colín R. Narcolepsy and orexins: an example of progress in sleep research. Front Neurol. 2011;2:26.
5. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369:499-511.
6. Mignot EJ. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics. 2012;9:739-52.
7. Broughton RJ, Fleming JA, George CF, Hill JD, Kryger MH, Moldofsky H, Montplaisir JY, Morehouse RL, Moscovitch A, Murphy WF. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 1997;49:444-51.
8. Kumar R. Approved and investigational uses of modafinil: an evidence-based review. Drugs. 2008;68:1803-39.
9. Myrick H, Malcolm R, Taylor B, LaRowe S. Modafinil: preclinical, clinical, and post-marketing surveillance: a review of abuse liability issues. Ann Clin Psychiatry. 2004;16:101-9.
10. Mignot E, Renaud A, Nishino S, Arrigoni J, Guilleminault C, Dement WC. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology. 1993;113:76-82.
11. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci. 2001;21(5):1787-94.
12. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, Wang GJ, Jayne M, Hooker JM, Wong C, Hubbard B, Carter P, Warner D, King P, Shea C, Xu Y, Muench L, Apelskog-Torres K. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301:1148-54.
13. Aagaard L, Hansen EH. The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies. Neuropsychiatr Dis Treat. 2011;7:729-44.
14. Rugino T. A review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescents. Neuropsychiatr Dis Treat. 2007;3:293-301.
15. Lecendreux M, Bruni O, Franco P, Gringras P, Konofal E, Nevsimalova S, Paiva T, Partinen M, Peeters E, Peraita-Adrados R, Plazzi G, Poli F. Clinical experience suggests that modafinil is an effective and safe treatment for paediatric narcolepsy. J Sleep Res. 2012;21:481-3.
16. Ivanenko A, Tauman R, Gozal D. Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med. 2003;4:579-82.
17. Dinges DF, Arora S, Darwish M, Niebler GE. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin. 2006;22:159-67.
18. Wise MS, Arand DL, Auger RR, Brooks SN, Watson NF, American Academy of Sleep Medicine. Treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30:1712-27.
19. Morgenthaler TI, Kapur VK, Brown T, Swick TJ, Alessi C, Aurora RN, Boehlecke B, Chesson AL Jr, Friedman L, Maganti R, Owens J, Pancer J, Zak R, Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30:1705-11.
20. De la Herrán-Arita AK, Equihua-Benítez AC, Drucker-Colín R. Treatment of cataplexy. Expert Opin Orphan Drugs. 2013;1:199-210.
21. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27:699-711.
22. Swanson J, Baler RD, Volkow ND. Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: a decade of progress. Neuropsychopharmacology. 2011;36:207-26.
23. Heil SH, Holmes HW, Bickel WK, Higgins ST, Badger GJ, Laws HF, Faries DE. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend. 2002;67:149-56.
24. Wee S, Woolverton WL. Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine. Drug Alcohol Depend. 2004;75:271-6.
25. Van Brunt DL, Johnston JA, Ye W, Pohl GM, Sun PJ, Sterling KL, Davis ME. Predictors of selecting atomoxetine therapy for children with attention-deficit-hyperactivity disorder. Pharmacotherapy. 2005;2511:1541-9.
26. Huang YS, Guilleminault C. Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate. Pediatr Neurol. 2009;41:9-16.
27. Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci. 1979;6:1-6.
28. Scharf MB, Lai AA, Branigan B, Stover R, Berkowitz DB. Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients. Sleep. 1998;21:507-14.
29. Black J, Pardi D, Hornfeldt CS, Inhaber N. The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy. J Clin Sleep Med. 2010;6:596-602.
30. Nissinen MJ, Karlstedt K, Castren E, Panula P. Expression of histidine decarboxylase and cellular histamine-like immunoreactivity in rat embryogenesis. J Histochem Cytochem. 1995;43:1241-52.
31. Parsons ME, Ganellin CR. Histamine and its receptors. Br J Pharmacol. 2006;147:S127-35.
32. Leurs R, Chazot PL, Shenton FC, Lim HD, de Esch IJ. Molecular and biochemical pharmacology of the histamine H4 receptor. Br J Pharmacol. 2009;157:14-23.
33. Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev. 2008;88:1183-241.
34. Ogawa S, Yanai K, Watanabe T, Wang ZM, Akaike H, Ito Y, Akaike N. Histamine responses of large neostriatal interneurons in histamine H1 and H2 receptor knock-out mice. Brain Res Bull. 2009;78:189-94.
35. Bayer L, Eggermann E, Serafin M, Saint-Mleux B, Machard D, Jones B, Mühlethaler M. Orexins (hypocretins) directly excite tuberomammillary neurons. Eur J Neurosci. 2001;14:1571-5.
36. -/- mice and patients. Neurobiol Dis. 2008;30:74-83.
37. Kanbayashi T, Kodama T, Kondo H, Satoh S, Inoue Y, Chiba S, Shimizu T, Nishino S. CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. Sleep. 2009;32:181-7.
38. Nishino S, Sakurai E, Nevsimalova S, Yoshida Y, Watanabe T, Yanai K, Mignot E. Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. Sleep. 2009;32:175-80.
39. Bassetti CL, Baumann CR, Dauvilliers Y, Croyal M, Robert P, Schwartz JC. Cerebrospinal fluid histamine levels are decreased in patients with narcolepsy and excessive daytime sleepiness of other origin. J Sleep Res. 2010;19:620-3.
40. Hondo M, Nagai K, Ohno K, Kisanuki Y, Willie JT, Watanabe T, Yanagisawa M, Sakurai T. Histamine-1 receptor is not required as a downstream effector of orexin-2 receptor in maintenance of basal sleep/wake states. Acta Physiol. 2010;198:287-94.
41. Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, Elmquist JK. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol. 2001;435:6-25.
42. Carter ME, Brill J, Bonnavion P, Huguenard JR, Huerta R, de Lecea L. Mechanism for hypocretin-mediated sleep-to-wake transitions. Proc Natl Acad Sci USA. 2012;25(109):E2635-44.
43. Inocente C, Arnulf I, Bastuji H, Thibault-Stoll A, Raoux A, Reimão R, Lin JS, Franco P. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol. 2012;35:55-60.
44. Barbier AJ, Berridge C, Dugovic C, Laposky AD, Wilson SJ, Boggs J, Aluisio L, Lord B, Mazur C, Pudiak CM, Langlois X, Xiao W, Apodaca R, Carruthers NI, Lovenberg TW. Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol. 2004;43:649-61.
45. Barbier AJ, Aluisio L, Lord B, Qu Y, Wilson SJ, Boggs JD, Bonaventure P, Miller K, Fraser I, Dvorak L, Pudiak C, Dugovic C, Shelton J, Mazur C, Letavic MA, Carruthers NI, Lovenberg TW. Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. Eur J Pharmacol. 2007;576:43-54.
46. Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, Cilia J, Cluderay JE, Crook B, Davis JB, Davis RK, Davis RP, Dawson LA, Foley AG, Gartlon J, Gonzalez MI, Heslop T, Hirst WD, Jennings C, Jones DN, Lacroix LP, Martyn A, Ociepka S, Ray A, Regan CM, Roberts JC, Schogger J, Southam E, Stean TO, Trail BK, Upton N, Wadsworth G, Wald JA, White T, Witherington J, Woolley ML, Worby A, Wilson DM. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther. 2007;321:1032-45.
47. Medhurst SJ, Collins SD, Billinton A, Bingham S, Dalziel RG, Brass A, Roberts JC, Medhurst AD, Chessell IP. Novel histamine H3 receptor antagonists GSK189254 and GSK334429 are efficacious in surgically-induced and virally-induced rat models of neuropathic pain. Pain. 2008;138:61-9.
48. -/- mice. Br J Pharmacol. 2009;157:104-17.
49. De La Herrán-Arita AK, Zomosa-Signoret VC, Millán-Aldaco DA, Palomero-Rivero M, Guerra-Crespo M, Drucker-Colín R, Vidaltamayo R. Aspects of the narcolepsy-cataplexy syndrome in O/E3-null mutant mice. Neuroscience. 2011;183:134-43.
50. Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci USA. 2004;101:4649-54.
51. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98:365-76.
52. Schatzberg SJ, Cutter-Schatzberg K, Nydam D, Barrett J, Penn R, Flanders J, de Lahunta A, Lin L, Mignot E. The effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy. J Vet Intern Med. 2004;18:586-8.
53. Hanson LR, Martinez PM, Taheri S. Intranasal administration of hypocretin-1 (orexin A) bypasses the blood-brain barrier and targets the brain: a new strategy for the treatment of narcolepsy. Drug Deliv Technol. 2004;4:66-71.
54. Baier PC, Hallschmid M, Seeck-Hirschner M, Weinhold SL, Burkert S, Diessner N, Göder R, Aldenhoff JB, Hinze-Selch D. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med. 2011;12:941-6.
55. Darker JG, Porter RA, Eggleston DS, Smart D, Brough SJ, Sabido-David C, Jerman JC. Structure-activity analysis of truncated orexin-A analogues at the orexin-1 receptor. Bioorg Med Chem Lett. 2001;11:737-40.
56. Vaughan JM, Fischer WH, Hoeger C, Rivier J, Vale W. Characterization of melanin-concentrating hormone from rat hypothalamus. Endocrinology. 1989;125:1660-5.
57. Bittencourt J, Celis M. Anatomy, function and regulation of neuropeptide EI (NEI). Peptides. 2008;29:1441-50.
58. Tan CP, Sano H, Iwaasa H, Pan J, Sailer AW, Hreniuk DL, Feighner SD, Palyha OC, Pong SS, Figueroa DJ, Austin CP, Jiang MM, Yu H, Ito J, Ito M, Ito M, Guan XM, MacNeil DJ, Kanatani A, Van der Ploeg LH, Howard AD. Melanin-concentrating hormone receptor subtypes 1 and 2: species-specific gene expression. Genomics. 2002;79:785-92.
59. Elias C, Sita L, Zambon B, Oliveira E, Vasconcelos L, Bittencourt J. Melanin-concentrating hormone projections to areas involved in somatomotor responses. J Chem Neuroanat. 2008;35:188-201.
60. Hong E, Yoon Y, Lee H. Differential distribution of melanin-concentrating hormone (MCH)- and hypocretin (Hcrt)-immunoreactive neurons projecting to the mesopontine cholinergic complex in the rat. Brain Res. 2011;1424:20-31.
61. Hassani OK, Lee MG, Jones BE. Melanin-concentrating hormone neurons discharge in a reciprocal manner to orexin neurons across the sleep-wake cycle. Proc Natl Acad Sci USA. 2009;106:2418-22.
62. Verret L, Goutagny R, Fort P, Cagnon L, Salvert D, Léger L, Boissard R, Salin P, Peyron C, Luppi PH. A role of melanin-concentrating hormone producing neurons in the central regulation of paradoxical sleep. BMC Neurosci. 2003;4:19.
63. Willie JT, Sinton CM, Maratos-Flier E, Yanagisawa M. Abnormal response of melanin-concentrating hormone deficient mice to fasting: hyperactivity and rapid eye movement sleep suppression. Neuroscience. 2008;156:819-29.
64. Saito Y, Nothacker HP, Wang Z, Lin SH, Leslie F, Civelli O. Molecular characterization of the melanin-concentrating-hormone receptor. Nature. 1999;400:265-9.
65. Guan JL, Uehara K, Lu S, Wang QP, Funahashi H, Sakurai T, Yanagisawa M, Shioda S. Reciprocal synaptic relationship between orexin-and melanin-concentrating hormone-containing neurons in the rat lateral hypothalamus: a novel circuit implicated in feeding regulation. Int J Obes Relat Metab Disord. 2002;26:1523-32.
66. Torterolo P, Sampogna S, Morales FR, Chase MH. MCH-containing neurons in the hypothalamus of the cat: searching for a role in the control of sleep and wakefulness. Brain Res. 2006;1119:101-14.
67. Backberg M, Hervieu G, Wilson S, Meister B. Orexin receptor-1 (OX-R1) immunoreactivity in chemically identified neurons of the hypothalamus: focus on orexin targets involved in control of food and water intake. Eur J Neurosci. 2002;15:315-28.
68. van den Pol AN, Acuna-Goycolea C, Clark KR, Ghosh PK. Physiological properties of hypothalamic MCH neurons identified with selective expression of reporter gene after recombinant virus infection. Neuron. 2004;42:635-52.
69. Rao Y, Lu M, Ge F, Marsh DJ, Qian S, Wang AH, Picciotto MR, Gao XB. Regulation of synaptic efficacy in hypocretin/orexin-containing neurons by melanin concentrating hormone in the lateral hypothalamus. J Neurosci. 2008;2008(28):9101-10.
70. Gehlert DR, Rasmussen K, Shaw J, Li X, Ardayfio P, Craft L, Coskun T, Zhang HY, Chen Y, Witkin JM. Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression. J Pharmacol Exp Ther. 2009;329:429-38.
71. Mahlios J, De la Herrán-Arita AK, Mignot E. The autoimmune basis of narcolepsy. Curr Opin Neurobiol. 2013. doi: 10.1016/j.conb.2013.04.013.
72. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA. 1994;91:123-7.
73. Wang B, Tisch R. Parameters influencing antigen-specific immunotherapy for type 1 diabetes. Immunol Res. 2008;42(1-3):246-58. doi: 10.1007/s12026-008- 8090-5.